Intellia Therapeutics (NTLA) Q1 2024 Earnings
NTLA·Reported May 9, 2024·Before market open
Intellia Therapeutics reported Q1 2024 revenue of $28.9M, beat analyst consensus of $11.5M by $17.4M. Diluted EPS came in at $-1.06, beat the $-1.35 consensus by $0.29.
Revenue
$28.9Mbeat by $17.4M
Consensus: $11.5MDiluted EPS
$-1.06beat by $0.29
Consensus: $-1.35
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Intellia Therapeutics's Q1 2024 earnings report.
Intellia Therapeutics (NTLA) reported Q1 2024 earnings on May 9, 2024 before market open.
Intellia Therapeutics reported revenue of $28.9M and diluted EPS of $-1.06 for Q1 2024.
Revenue beat the consensus estimate of $11.5M by $17.4M. EPS beat the consensus estimate of $-1.35 by $0.29.
You can read the 10-Q periodic report (0000950170-24-057046) directly on SEC EDGAR. The filing index links above go to sec.gov.